Get started
Author

Timothy Wohlfromm

Observed name: T. Wohlfromm
OpenAlex ID: A5083030461
Nivolumab and ipilimumab in recurrent or refractory cancer of unknown primary: a phase II trial
2023 · Maria Pouyiourou, Bianca N. Kraft, et al. · Nature Communications · 45
PDF
Local ablative treatment with surgery and/or radiotherapy in single-site and oligometastatic carcinoma of unknown primary
2021 · Maria Pouyiourou, Timothy Wohlfromm, et al. · European Journal of Cancer · 19
Prognostic impact of copy number alterations and tumor mutational burden in carcinoma of unknown primary
2022 · Tilmann Bochtler, Timothy Wohlfromm, et al. · Genes Chromosomes and Cancer · 14
PDF
STIL overexpression shortens lifespan and reduces tumor formation in mice
2024 · Amira-Talaat Moussa, Marco R. Cosenza, et al. · PLoS Genetics · 7
738P Combined ipilimumab and nivolumab in previously treated patients with cancer of unknown primary: Results of the CheCUP trial
2022 · M. Pouyiourou, B. Kraft, et al. · Annals of Oncology · 3
43P Influence of chromosomal instability on cGAS/STING activation and metastatic behavior of lung and colorectal cancer cells
2022 · G.M. Mühlmeier, B. Kraft, et al. · Annals of Oncology · 1
Author Reply to Peer Reviews of STIL overexpression shortens lifespan and reduces tumor formation in mice
2024 · Amira Talaat Moussa, Marco R Cosenza, et al.
Works count: 7
Citation count: 89
H-index: 4
I10-index: 3
Year
Topic
Type